De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Emergent BioSolutions Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Joe Papa

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.7yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

CEO

Joe Papa (68 yo)

less than a year

Tenure

Mr. Joseph C. Papa, Jr. also known as Joe, is Director of Milestone Pharmaceuticals Inc. since September 3, 2024. Mr. Papa serves as Executive Advisor at Water Street Healthcare Partners, LLC since joining...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Lindahl	Executive VP	6.6yrs	US$2.18m	0.29% $ 1.5m
Coleen Glessner	Executive Vice President of Global Quality and Ethics & Compliance	2.5yrs	US$1.68m	0.30% $ 1.5m
Paul Williams	Senior Vice President of Products Business	1.8yrs	US$1.06m	0.045% $ 227.5k
Joseph Papa	CEO, President & Director	less than a year	geen gegevens	geen gegevens
Jessica Perl	Corporate Secretary and Interim General Counsel	less than a year	geen gegevens	geen gegevens
Michelle Pepin	Senior VP & Chief Human Resource Officer	1.6yrs	geen gegevens	geen gegevens
Stephanie Duatschek	Senior VP	1.6yrs	geen gegevens	geen gegevens
Kelly Warfield	Senior VP of Science & Development	1.8yrs	geen gegevens	geen gegevens
William Hartzel	Senior Vice President of Manufacturing & Bioservices	no data	geen gegevens	0.089% $ 449.8k

1.7yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0IGA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Papa	CEO, President & Director	less than a year	geen gegevens	geen gegevens
Louis Sullivan	Independent Director	18.3yrs	US$400.23k	0.099% $ 499.5k
Ronald Richard	Independent Director	19.8yrs	US$394.73k	0.037% $ 185.5k
Donald DeGolyer	Independent Director	less than a year	US$397.50k	geen gegevens
Keith Katkin	Independent Director	2.5yrs	US$396.99k	0.011% $ 53.6k
Marvin White	Independent Director	4yrs	US$405.98k	0.032% $ 159.9k
Zsolt Harsanyi	Independent Non-Executive Chairman	20.2yrs	US$535.98k	0.070% $ 355.8k
Kathryn Zoon	Independent Director	7.9yrs	US$413.48k	0.069% $ 346.4k
Neal Fowler	Independent Director	less than a year	US$398.75k	geen gegevens
Sujata Dayal	Independent Director	2.3yrs	US$382.23k	0.0073% $ 36.9k

3.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0IGA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Emergent BioSolutions Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

High number of new directors

Emergent BioSolutions Inc., Annual General Meeting, May 23, 2024

High number of new directors

Emergent BioSolutions Inc. Announces Changes in CEO

Emergent Biosolutions Inc. Announces Board Appointments

Emergent BioSolutions Inc. Announces Demise of Jerome Hauer, Ph.D., Director

Recent updates

Emergent BioSolutions’ ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

New minor risk - Profitability

Second quarter 2024 earnings released: US$5.38 loss per share (vs US$5.22 loss in 2Q 2023)

Emergent BioSolutions Inc. Updates Earnings Guidance for the Full Year of 2024

High number of new directors

Emergent BioSolutions Inc. to Report Q2, 2024 Results on Aug 06, 2024

Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 3000 Index

Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

Emergent BioSolutions Inc. to Report Q1, 2024 Results on May 01, 2024

New minor risk - Market cap size

Emergent BioSolutions Inc., Annual General Meeting, May 23, 2024

High number of new directors

Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

Full year 2023 earnings released: US$14.85 loss per share (vs US$4.22 loss in FY 2022)

Emergent BioSolutions Inc. Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Full Year of 2024

Emergent BioSolutions Inc. to Report Q4, 2023 Results on Mar 06, 2024

Emergent BioSolutions Inc. Announces Changes in CEO

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Emergent BioSolutions Inc. announced delayed 10-Q filing

Emergent BioSolutions Inc. Updates Earnings Guidance for the Year 2023

Emergent BioSolutions Inc. to Report Q3, 2023 Results on Nov 02, 2023

Emergent Biosolutions Inc. Announces Board Appointments

Emergent Biosolutions' Narcan®? Nasal Spray Launches over the Counter Making It Possible for Everyone to Help Save A Life from an Opioid Overdose Emergency

Emergent BioSolutions Inc. Announces Demise of Jerome Hauer, Ph.D., Director

Emergent BioSolutions Inc. Reports Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2023

Emergent BioSolutions Inc. Announces Executive Changes

Emergent BioSolutions Inc. to Report Q2, 2023 Results on Aug 08, 2023

Emergent BioSolutions Inc. Receives U.S. FDA Approval of CYFENDUS ( Anthrax Vaccine Adsorbed, Adjuvanted), A Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Emergent BioSolutions Inc. Announces Resignation of Robert G. Kramer Sr. as President and Member of the Company's Board

Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 2000 Value-Defensive Index

First quarter 2023 earnings released: US$3.65 loss per share (vs US$0.073 loss in 1Q 2022)

Emergent Biosolutions Inc. Revises Earnings Guidance for the Full Year of 2023

Full year 2022 earnings released: US$4.47 loss per share (vs US$4.32 profit in FY 2021)

Emergent BioSolutions Inc. Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

Investor sentiment improves as stock rises 19%

Emergent BioSolutions Inc. to Report Q4, 2022 Results on Feb 27, 2023

Emergent Biosolutions Inc. Announces Executive Changes

Investor sentiment improved over the past week

Emergent BioSolutions Inc. Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-The-Counter NARCAN® (Naloxone HCI) Nasal Spray

Investor sentiment deteriorated over the past week

Now 49% undervalued after recent price drop

Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2022

Emergent BioSolutions Inc. Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

Emergent BioSolutions Inc. to Report Q3, 2022 Results on Nov 08, 2022

Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million.

Emergent BioSolutions Inc. Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

Now 22% undervalued after recent price drop

Second quarter 2022 earnings released: US$1.13 loss per share (vs US$0.086 profit in 2Q 2021)

Now 31% undervalued after recent price drop

Emergent BioSolutions Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022

Emergent Biosolutions Announces Appointment of Sujata Dayal to Board of Directors, Member of the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight, Effective July 15, 2022

Emergent BioSolutions Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate

Emergent BioSolutions Inc. Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Investor sentiment improved over the past week

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

First quarter 2022 earnings released: US$0.073 loss per share (vs US$1.31 profit in 1Q 2021)

Emergent BioSolutions Inc., Annual General Meeting, May 26, 2022

Emergent BioSolutions Inc. to Report Q1, 2022 Results on Apr 28, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Emergent BioSolutions Inc. Provides Revenue Guidance for First Quarter of 2022

Emergent BioSolutions Inc. Reports Goodwill Impairment for the Fourth Quarter Ended December 31, 2021

Emergent BioSolutions Inc. to Report Q4, 2021 Results on Feb 24, 2022

Emergent BioSolutions Inc. Provides Earnings Guidance for the Full Year 2022

Emergent BioSolutions Inc Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate

Executive VP recently bought US$112k worth of stock